# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 11, "Clin Ther .", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasJournal> \"Clin Ther .\"."
2, PublicationYear, 12, 16, "2006", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasPublicationYear> \"2006\"."
253, Title, 47, 299, "Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel - group study .", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasTitle> \"Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week , multicenter , randomized , double - blind , placebo - controlled , parallel - group study .\"."
3, Sitagliptin, 109, 120, "sitagliptin", "", 
4, Pioglitazone, 138, 150, "pioglitazone", "", 
5, Type2Diabetes, 176, 191, "type 2 diabetes", "", 
6, Duration, 196, 205, "24 - week", "", 
7, Multicenter, 208, 219, "multicenter", "", 
8, Randomized, 222, 232, "randomized", "", 
9, DoubleBlind, 235, 249, "double - blind", "", 
10, Placebo, 252, 259, "placebo", "", 
11, Parallel, 275, 291, "parallel - group", "", 
13, Author, 300, 312, "Rosenstock J", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasAuthor> \"Rosenstock J\"."
14, Author, 321, 328, "Brazg R", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasAuthor> \"Brazg R\"."
15, Author, 331, 341, "Andryuk PJ", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasAuthor> \"Andryuk PJ\"."
16, Author, 344, 348, "Lu K", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasAuthor> \"Lu K\"."
17, Author, 351, 358, "Stein P", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasAuthor> \"Stein P\"."
18, USA, 474, 477, "USA", "", 
159, ObjectiveDescription, 492, 613, "The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasObjectiveDescription> \"The efficacy and tolerability of the dipeptidyl peptidase - 4 inhibitor sitagliptin added to ongoing pioglitazone therapy\"."
19, Sitagliptin, 564, 575, "sitagliptin", "", 
20, Pioglitazone, 593, 605, "pioglitazone", "", 
255, ObjectiveDescription, 614, 810, "were assessed in patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone .", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasObjectiveDescription> \"were assessed in patients with type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone .\"."
158, Precondition, 645, 808, "type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone", "", "<http://ctro/data#Population_42353> <http://ctro/data#hasPrecondition> \"type 2 diabetes and inadequate glycemic control ( glycosylated hemoglobin [ HbA ( 1c ) ] > or = 7 % and < or = 10 % ) while receiving a stable dose of pioglitazone\"."
21, Type2Diabetes, 645, 660, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
153, HbA1c, 695, 718, "glycosylated hemoglobin", "", 
154, HbA1c, 721, 731, "HbA ( 1c )", "", 
155, Percentage, 743, 744, "%", "", 
156, Percentage, 759, 760, "%", "", 
23, Pioglitazone, 796, 808, "pioglitazone", "", 
26, Duration, 832, 841, "24 - week", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasCTduration> \"24 - week\"."
27, Multicenter, 844, 855, "multicenter", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
28, Randomized, 858, 868, "randomized", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
29, DoubleBlind, 871, 885, "double - blind", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
30, Placebo, 888, 895, "placebo", "", 
31, Parallel, 911, 925, "parallel group", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
32, MinAge, 956, 958, "18", "", "<http://ctro/data#Population_42353> <http://ctro/data#hasMinAge> \"18\"."
33, Pioglitazone, 1162, 1174, "pioglitazone", "", 
35, Duration, 1226, 1242, "8 - to 14 - week", "", 
36, OpenLabel, 1243, 1255, "open - label", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasCTDesign> <http://ctro/data#OpenLabel>."
37, Pioglitazone, 1256, 1268, "pioglitazone", "", 
167, HbA1c, 1328, 1338, "HbA ( 1c )", "", 
168, Percentage, 1348, 1349, "%", "", 
169, Percentage, 1364, 1365, "%", "", 
268, TimePoint, 1369, 1391, "the end of this period", "", 
38, Duration, 1402, 1410, "2 - week", "", 
39, Blind, 1413, 1427, "single - blind", "", "<http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasCTDesign> <http://ctro/data#Blind>."
40, Placebo, 1430, 1437, "placebo", "", 
41, Duration, 1498, 1506, "21 weeks", "", 
43, Pioglitazone, 1543, 1555, "pioglitazone", "", 
44, DoseValue, 1570, 1572, "30", "", 
45, DoseValue, 1576, 1578, "45", "", 
48501, mg, 1579, 1581, "mg", "", 
48502, Interval, 1584, 1585, "d", "", 
174, HbA1c, 1599, 1609, "HbA ( 1c )", "", 
175, Percentage, 1619, 1620, "%", "", 
176, Percentage, 1635, 1636, "%", "", 
47, Duration, 1649, 1657, "2 - week", "", 
48, Blind, 1660, 1674, "single - blind", "", 
49, Placebo, 1677, 1684, "placebo", "", 
51, Randomized, 1734, 1747, "randomization", "", 
52, Pioglitazone, 1786, 1798, "pioglitazone", "", 
53, DoseValue, 1801, 1803, "30", "", 
54, DoseValue, 1807, 1809, "45", "", 
180, mg, 1810, 1812, "mg", "", 
48505, Interval, 1815, 1816, "d", "", 
56, Randomized, 1835, 1845, "randomized", "", 
183, AllocationRatio, 1851, 1856, "1 : 1", "", "<http://ctro/data#AllocationRatio_42335> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_42331> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_42335>."
57, Sitagliptin, 1874, 1885, "sitagliptin", "", "<http://ctro/data#Medication_42429> <http://ctro/data#hasDrug> <http://ctro/data#Sitagliptin>."
58, DoseValue, 1886, 1889, "100", "", "<http://ctro/data#Medication_42429> <http://ctro/data#hasDoseValue> \"100\"."
59, mg, 1890, 1892, "mg", "", "<http://ctro/data#Medication_42429> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
60, Frequency, 1893, 1903, "once daily", "", "<http://ctro/data#Intervention_42409> <http://ctro/data#hasFrequency> \"once daily\"."
61, Placebo, 1907, 1914, "placebo", "", "<http://ctro/data#Medication_42436> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
62, Duration, 1919, 1927, "24 weeks", "", 
257, TimePoint, 1981, 1989, "baseline", "", 
63, HbA1c, 1993, 2003, "HbA ( 1c )", "", 
258, TimePoint, 2007, 2014, "week 24", "", 
259, TimePoint, 2072, 2080, "baseline", "", 
191, FastingPlasmaGlucose, 2084, 2106, "fasting plasma glucose", "", 
192, FastingPlasmaGlucose, 2109, 2112, "FPG", "", 
260, InsulinDose, 2117, 2124, "insulin", "", 
67, EndPointDescription, 2131, 2141, "proinsulin", "", 
194, EndPointDescription, 2148, 2197, "Homeostasis Model Assessment beta - cell function", "", 
69, EndPointDescription, 2202, 2230, "insulin - resistance indexes", "", 
70, EndPointDescription, 2237, 2263, "proinsulin / insulin ratio", "", 
71, EndPointDescription, 2270, 2314, "Quantitative Insulin Sensitivity Check Index", "", 
261, TimePoint, 2342, 2350, "baseline", "", 
72, EndPointDescription, 2354, 2379, "selected lipid parameters", "", 
198, HbA1c_target, 2451, 2481, "HbA ( 1c ) , goal of < 7 . 0 %", "", 
75, EndPointDescription, 2488, 2545, "proportion of patients requiring metformin rescue therapy", "", 
74, Metformin, 2521, 2530, "metformin", "", 
76, EndPointDescription, 2556, 2596, "time to the initiation of rescue therapy", "", 
201, NumberPatientsArm, 2609, 2635, "One hundred seventy - five", "", "<http://ctro/data#Arm_42391> <http://ctro/data#hasNumberPatientsArm> \"One hundred seventy - five\"."
77, Randomized, 2650, 2660, "randomized", "", 
78, Sitagliptin, 2672, 2683, "sitagliptin", "", 
79, NumberPatientsArm, 2690, 2693, "178", "", "<http://ctro/data#Arm_42400> <http://ctro/data#hasNumberPatientsArm> \"178\"."
81, Randomized, 2699, 2709, "randomized", "", 
82, Placebo, 2721, 2728, "placebo", "", 
83, Mean, 2735, 2739, "mean", "", "<http://ctro/data#Mean_42363> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_42361> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_42363>."
266, TimePoint, 2747, 2755, "baseline", "", 
84, HbA1c, 2756, 2761, "HbAlc", "", "<http://ctro/data#Endpoint_42361> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
85, BaseLineValue, 2772, 2777, "8 . 1", "", "<http://ctro/data#Outcome_42443> <http://ctro/data#hasBaselineValue> \"8 . 1\"."
87, Percentage, 2778, 2779, "%", "", "<http://ctro/data#Endpoint_42361> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
86, SdDevBL, 2782, 2787, "0 . 8", "", "<http://ctro/data#Outcome_42443> <http://ctro/data#hasSdDevBL> \"0 . 8\"."
88, Sitagliptin, 2797, 2808, "sitagliptin", "", 
89, BaseLineValue, 2819, 2824, "8 . 0", "", "<http://ctro/data#Outcome_42470> <http://ctro/data#hasBaselineValue> \"8 . 0\"."
90, Percentage, 2825, 2826, "%", "", 
91, SdDevBL, 2829, 2834, "0 . 8", "", "<http://ctro/data#Outcome_42470> <http://ctro/data#hasSdDevBL> \"0 . 8\"."
92, Placebo, 2844, 2851, "placebo", "", 
94, TimePoint, 2860, 2874, "After 24 weeks", "", "<http://ctro/data#Outcome_42443> <http://ctro/data#hasTimePoint> \"After 24 weeks\". <http://ctro/data#Outcome_42470> <http://ctro/data#hasTimePoint> \"After 24 weeks\"."
93, Sitagliptin, 2877, 2888, "sitagliptin", "", 
95, Pioglitazone, 2898, 2910, "pioglitazone", "", 
96, Placebo, 2976, 2983, "placebo", "", 
97, HbA1c, 2987, 2997, "HbA ( 1c )", "", 
98, LeastSquaresMean, 3034, 3059, "least squares [ LS ] mean", "", 
267, TimePoint, 3072, 3080, "baseline", "", 
99, DiffGroupAbsValue, 3083, 3091, "- 0 . 70", "", "<http://ctro/data#DiffBetweenGroups_42497> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 70\"."
100, Percentage, 3092, 3093, "%", "", 
101, ConfIntervalDiff, 3096, 3126, "95 % CI , - 0 . 85 to - 0 . 54", "", "<http://ctro/data#DiffBetweenGroups_42497> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 0 . 85 to - 0 . 54\"."
102, PvalueDiff, 3129, 3140, "P < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_42497> <http://ctro/data#hasPvalueDiff> \"P < 0 . 001\"."
103, FastingPlasmaGlucose, 3147, 3150, "FPG", "", "<http://ctro/data#Endpoint_42366> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
104, DiffGroupAbsValue, 3153, 3161, "- 17 . 7", "", "<http://ctro/data#DiffBetweenGroups_42506> <http://ctro/data#hasDiffGroupAbsValue> \"- 17 . 7\"."
105, Mg_per_deciliter, 3162, 3169, "mg / dL", "", "<http://ctro/data#Endpoint_42366> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Mg_per_deciliter>."
106, ConfIntervalDiff, 3172, 3202, "95 % CI , - 24 . 3 to - 11 . 0", "", "<http://ctro/data#DiffBetweenGroups_42506> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 24 . 3 to - 11 . 0\"."
107, PvalueDiff, 3205, 3216, "P < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_42506> <http://ctro/data#hasPvalueDiff> \"P < 0 . 001\"."
108, Mean, 3221, 3225, "Mean", "", 
109, HbA1c, 3226, 3236, "HbA ( 1c )", "", 
110, TimePoint, 3247, 3256, "end point", "", 
111, ResultMeasuredValue, 3262, 3267, "7 . 2", "", "<http://ctro/data#Outcome_42443> <http://ctro/data#hasResultMeasuredValue> \"7 . 2\"."
112, Percentage, 3268, 3269, "%", "", 
113, SdDevResValue, 3272, 3277, "0 . 9", "", "<http://ctro/data#Outcome_42443> <http://ctro/data#hasSdDevResValue> \"0 . 9\"."
114, ResultMeasuredValue, 3284, 3289, "7 . 8", "", "<http://ctro/data#Outcome_42470> <http://ctro/data#hasResultMeasuredValue> \"7 . 8\"."
115, Percentage, 3290, 3291, "%", "", 
116, SdDevResValue, 3294, 3299, "1 . 1", "", "<http://ctro/data#Outcome_42470> <http://ctro/data#hasSdDevResValue> \"1 . 1\"."
237, HbA1c_target, 3382, 3412, "target HbA ( 1c ) of < 7 . 0 %", "", "<http://ctro/data#Endpoint_42371> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
118, PercentageAffected, 3418, 3424, "45 . 4", "", "<http://ctro/data#Outcome_42569> <http://ctro/data#hasPercentageAffected> \"45 . 4\"."
121, PercentageAffected, 3431, 3437, "23 . 0", "", "<http://ctro/data#Outcome_42596> <http://ctro/data#hasPercentageAffected> \"23 . 0\"."
122, PvalueDiff, 3442, 3453, "P < 0 . 001", "", "<http://ctro/data#Outcome_42596> <http://ctro/data#hasPercentageAffected> \"23 . 0\"."
127, ObservedResult, 3458, 3480, "Significant reductions", "", "<http://ctro/data#Outcome_42632> <http://ctro/data#hasObservedResult> \"Significant reductions\". <http://ctro/data#Outcome_42659> <http://ctro/data#hasObservedResult> \"Significant reductions\"."
123, EndPointDescription, 3484, 3515, "fasting serum proinsulin levels", "", "<http://ctro/data#EndPointDescription_42377> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_42376> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_42377>."
124, EndPointDescription, 3524, 3550, "proinsulin / insulin ratio", "", "<http://ctro/data#EndPointDescription_42382> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_42381> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_42382>."
125, Sitagliptin, 3566, 3577, "sitagliptin", "", 
126, Placebo, 3602, 3609, "placebo", "", 
244, PValueChangeValue, 3619, 3629, "P < 0 . 01", "", "<http://ctro/data#Outcome_42632> <http://ctro/data#hasPValueChangeValue> \"P < 0 . 01\". <http://ctro/data#Outcome_42659> <http://ctro/data#hasPValueChangeValue> \"P < 0 . 01\"."
129, Sitagliptin, 3634, 3645, "Sitagliptin", "", 
251, ObservedResult, 3682, 3699, "no increased risk", "", "<http://ctro/data#Outcome_42686> <http://ctro/data#hasObservedResult> \"no increased risk\"."
247, Hypoglycemia, 3703, 3715, "hypoglycemia", "", "<http://ctro/data#Endpoint_42386> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
131, Placebo, 3730, 3737, "placebo", "", 
132, NumberAffected, 3740, 3741, "2", "", "<http://ctro/data#Outcome_42686> <http://ctro/data#hasNumberAffected> \"2\"."
133, NumberAffected, 3745, 3746, "0", "", 
134, PMID, 3832, 3840, "17157112", "", "<http://ctro/data#Publication_42320> <http://ctro/data#hasPMID> \"17157112\"."
